On Monday, First Industrial Realty Trust, Inc. (NYSE:FR)’s shares inclined 0.25% to $19.73.
First Industrial Realty Trust, Inc. (FR), a leading fully-integrated owner, operator and developer of industrial real estate, recently declared the closing of a new $260 million unsecured term loan with a seven-year term. The loan features interest-only payments and initially bears an interest rate of LIBOR plus 160 basis points. The rate is subject to adjustment based on the Company’s leverage or credit ratings.
The Company also reached interest rate swap agreements to effectively convert the loan’s rate to a fixed interest rate of about 3.39% per annum based on the loan’s current credit spread. The Company plans to initially use the proceeds to repay amounts outstanding under its unsecured credit facility and for other general business purposes.
Wells Fargo Securities, LLC, PNC Capital Markets LLC, Regions Capital Markets and U.S. Bank National Association served as joint-lead arrangers and joint book runners for the term loan. In addition, Wells Fargo Bank, National Association acted as the Administrative Agent. PNC Bank, National Association, Regions Bank and U.S. Bank National Association served as Co-Syndication Agents. Associated Bank and Fifth Third Bank also take partd in the loan.
First Industrial Realty Trust Inc. is a real estate investment trust. The firm invests in the real estate markets of the United States. It makes investments in industrial properties. The firm owns, manages, acquires, sells, develops, and redevelops industrial real estate. First Industrial Realty Trust Inc. formed on August 10, 1993 and is domiciled in the United States.
Axovant Sciences Ltd (NYSE:AXON)’s shares gained 13.01% to $16.59.
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, recently declared forthcoming presentations at the Credit Suisse SMID Conference in New York at the Waldorf Astoria New York on Thursday, September 17 at 9:30 AM.
Axovant’s administration team will present an overview of the company and its lead product candidate, RVT-101, which is predictable to enter a confirmatory phase 3 trial for the treatment of mild-to-moderate Alzheimer’s disease in the fourth calendar quarter of 2015.
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics for the treatment of neurodegenerative disorders. It develops RVT-101, a product candidate that plans to commence a Phase III pivotal program for the treatment of Alzheimer’s disease and other forms of dementia.
At the end of Monday’s trade, Synovus Financial Corp. (NYSE:SNV)‘s shares surged 0.73% to $30.46.
Synovus Financial Corp. (SNV) Chairman and CEO Kessel Stelling will present at the Barclays Global Financial Services Conference in New York on Wednesday, September 16, 2015, at 2:00 p.m. ET.
Synovus Financial Corp. operates as the bank holding company for Synovus Bank that provides various financial products and services. It offers integrated financial services, counting commercial and retail banking, financial administration, insurance, and mortgage services. The company’s commercial banking services comprise cash administration, asset administration, capital markets services, and institutional trust services, in addition to commercial, financial, and real estate loans. Its retail banking services comprise of accepting various types of demand and savings deposits; mortgage, installment, and other retail loans; investment and brokerage services; safe deposit services; automated banking services; automated fund transfers; Internet based banking services; and bank credit card services, counting MasterCard and Visa services.
F.N.B. Corp (NYSE:FNB), ended its Monday’s trading session with -0.16% loss, and closed at $12.80.
F.N.B. Corporation (FNB) and Metro Bancorp, Inc. (METR) jointly declared the signing of a definitive merger agreement following which F.N.B. Corporation will acquire Metro Bancorp, Inc., the holding company and parent of Metro Bank, in an all stock transaction valued at about $32.72 per share, or $474 million in the aggregate, using the closing stock price of FNB as of Monday, August 3, 2015.
The acquisition of the Harrisburg-based bank will provide FNB with about $3.0 billion in total assets, counting $2.4 billion in total deposits, $2.1 billion in total loans and 32 banking offices located in the Harrisburg, York, Lancaster, Reading and Lebanon MSAs. The transaction will enhance FNB’s distribution and scale across Central Pennsylvania and strengthen its position as the largest Pennsylvania-based regional bank, moving its state deposit market share rank to a top five position. With the acquisition of Metro, FNB will have $19.6 billion in assets, counting $14.7 billion in total deposits, $13.7 billion in total loans and more than 300 full service banking offices.
F.N.B. Corporation, a financial holding company, provides various financial services to consumers, corporations, governments, and small- to medium-sized businesses primarily in Pennsylvania, eastern Ohio, and northern West Virginia. It operates through four segments: Community Banking, Wealth Administration, Insurance, and Consumer Finance. The Community Banking segment offers various services, counting commercial and individual demand, savings, and time deposit accounts; and commercial, mortgage, and individual installment loans.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
